Respiratory tract infection

Even before the Covid-19 pandemic, RTIs were a leading cause of hospitalization in children, many of whom may go on to develop chronic conditions such as asthma.

A case study to learn more about the challenge of running clinical studies during pandemic lockdowns

OM Pharma wanted to assess the feasibility of running clinical trials of a treatment to prevent respiratory tract infections (RTIs) during the Covid-19 lockdown.

Nova built a multi-scale in silico model capturing how non-pharmaceutical interventions (NPI) – such as lockdown or mask-wearing – affect rates of infection with the most common respiratory viruses, and the impact of the prophylactic treatment OM-85 under different NPI scenarios in the context of an upcoming trial.

Summary

  1. About RTI
  2. How nova approached the challenge
  3. The outcomes

Download
case study

Get your questions answered by downloading the free pdf and learn more about our study!

  • Your information will be processed by Nova to send you the content requested. For more information about our processing or to exercise your GDPR rights, see our Privacy Policy
  • This field is for validation purposes and should be left unchanged.